- AstraZeneca’s newly approved pill fails frontline breast cancer studyEtcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
- FDA approves Scholar Rock's muscle-targeted SMA therapy IsembyldThe Food and Drug Administration has approved a new medication for spinal muscular atrophy (SMA). The drug, apitegromab marketed as Isembyld, is the first muscle-targeted therapy for the disease.…